Active surveillance versus initial surgery in the long-term management of Bosniak IIF-IV cystic renal masses

There may be surgical overtreatment of complex cystic renal masses (CRM). Growing evidence supports active surveillance (AS) for the management for Bosniak IIF-III CRMs. We aimed to evaluate and compare oncological and pathological outcomes of Bosniak IIF-IV CRMs treated by initial surgery (IS) or AS. We identified retrospectively 532 patients with CRM counseled during 2006-2017. IS and AS were delivered to, respectively, 1 and 286 patients in Bosniak IIF, to 54 and 85 patients in III and to 85 and 21 patients in Bosniak IV. Median follow-up was 66 months (IQR 50-96). Metastatic progression occurred for 1 (0.3%) AS patient in Bosniak IIF, 1 IS (1.8%) and 1 AS (1.2%) patient in Bosniak III and 5 IS (3.5%) patients in Bosniak IV, respectively. Overall 5-year metastasis-free survival was 98.9% and cancer-specific survival was 99.6% without statistically significant difference between IS and AS in Bosniak IIF-IV categories. AS did not increase the risk of metastatic spread or cancer-specific mortality in patients with Bosniak IIF-IV. Our data indicate AS in Bosniak IIF and III is safe. Surgery is the primary treatment for Bosniak IV due to its high malignancy rate.Peer reviewe

Munuaissyövän hoito edistyy

Vertaisarvioitu.• Munuaissyövän ennuste on parantunut: kolme neljästä sairastuneesta elää ainakin viisi vuotta. • Suurin osa munuaiskasvaimista on diagnosointihetkellä oireettomia. Diagnoosin varmistamiseksi tehdään vatsan alueen tietokonekuvaus erikoissairaanhoidossa. • Paikallisen taudin hoito on joko munuaisen osa- tai kokopoisto. • Levinneen munuaissyövän lääkehoito perustuu täsmälääkkeisiin sekä immuno-onkologisiin lääkehoitoihin. • Jälkiseurantaan kuuluvat kohdennetut laboratoriokokeet ja toistetut kuvantamistutkimukset.Peer reviewe